Matches in Wikidata for { <http://www.wikidata.org/entity/Q96820301> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q96820301 description "2020 թվականի հունիսի 11-ին հրատարակված գիտական հոդված" @default.
- Q96820301 description "article scientifique publié en 2020" @default.
- Q96820301 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96820301 description "scientific article published on 11 June 2020" @default.
- Q96820301 description "wetenschappelijk artikel" @default.
- Q96820301 description "наукова стаття, опублікована 11 червня 2020" @default.
- Q96820301 name "Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults" @default.
- Q96820301 name "Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults" @default.
- Q96820301 type Item @default.
- Q96820301 label "Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults" @default.
- Q96820301 label "Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults" @default.
- Q96820301 prefLabel "Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults" @default.
- Q96820301 prefLabel "Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults" @default.
- Q96820301 P1433 Q96820301-CDB2389A-B18D-43B5-9BEE-0FB7B467EDEF @default.
- Q96820301 P1476 Q96820301-61A1B658-8CDC-483A-B041-7C7D26F056F1 @default.
- Q96820301 P2093 Q96820301-2E51900F-F18A-4493-83F9-6206E68C67AC @default.
- Q96820301 P275 Q96820301-21d28b1f-3173-4782-91ea-09c09ffabbd4 @default.
- Q96820301 P304 Q96820301-AF6917F4-B704-45A0-8762-1503ABC0C56A @default.
- Q96820301 P31 Q96820301-96845F1F-C90B-41B5-8858-A2BFB5E16149 @default.
- Q96820301 P356 Q96820301-D33E3E8E-ACBD-4EB4-9A39-4574B79F7047 @default.
- Q96820301 P478 Q96820301-CB0370FD-563A-45D7-8AEF-55F278346A95 @default.
- Q96820301 P50 Q96820301-3414DEEA-4A83-41D6-BBD3-095707EF9F22 @default.
- Q96820301 P50 Q96820301-604D311D-3456-4A8B-9A7D-7D63B53529DD @default.
- Q96820301 P50 Q96820301-EC38E137-F269-4EFA-9529-6C17E4D0C5AF @default.
- Q96820301 P577 Q96820301-1F720096-7103-4098-BD04-5035FAD05DAD @default.
- Q96820301 P6216 Q96820301-bab5f1fa-6a5b-4176-926c-4cd562c4a46b @default.
- Q96820301 P698 Q96820301-99DB41EE-05CD-449B-9C79-1A09FAB5A3B0 @default.
- Q96820301 P921 Q96820301-3FD4E6E9-5B33-4A1B-88E1-C985629F14B8 @default.
- Q96820301 P356 CCID.S252426 @default.
- Q96820301 P698 32606876 @default.
- Q96820301 P1433 Q5133742 @default.
- Q96820301 P1476 "Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults" @default.
- Q96820301 P2093 "Tina Bhutani" @default.
- Q96820301 P275 Q18810331 @default.
- Q96820301 P304 "391-398" @default.
- Q96820301 P31 Q13442814 @default.
- Q96820301 P356 "10.2147/CCID.S252426" @default.
- Q96820301 P478 "13" @default.
- Q96820301 P50 Q47321890 @default.
- Q96820301 P50 Q90217056 @default.
- Q96820301 P50 Q94454808 @default.
- Q96820301 P577 "2020-06-11T00:00:00Z" @default.
- Q96820301 P6216 Q50423863 @default.
- Q96820301 P698 "32606876" @default.
- Q96820301 P921 Q10355321 @default.